No Data
Cornerstone Pharmaceuticals Group - B (02616) will announce the latest clinical data of CS5001 for lymphoma at the 66th American Society of Hematology (ASH) Annual Meeting.
Cornerstone Pharmaceuticals-B (02616) announced that the company will present at the 66th American Society of Hematology (ASH) Annual Meeting...
CStone Drug Gets UK Approval for First-Line Treatment of Non-Small Cell Lung Cancer
Cornerstone Pharmaceuticals-B (02616.HK) Regorafenib Monoclonal Antibody approved by the United Kingdom Medicines and Healthcare Products Regulatory Agency for first-line treatment of non-small cell lung cancer
October 31, Grong Hui丨Cornerstone Pharmaceuticals-B (02616.HK) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has approved the combination of Sogelid ankagen with platinum-based chemotherapy for first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) without sensitive EGFR mutations, or ALK, ROS1, RET gene tumor mutations. This is the second marketing authorization approval obtained by Sogelid ankagen in overseas markets following the approval of the European Commission. Key highlights• This is the second approval obtained by Sogelid ankagen outside of China following the approval of the European Commission.
Express News | UK's Mhra: Sugemalimab Approved to Treat Adult Patients With Non-Small Cell Lung Cancer
Cornerstone Pharmaceuticals-B (02616.HK) announces the publication of the results of the population pharmacokinetics study of Zekkeimei (Durvalumab Injection) in the British Journal of Clinical Pharmacology.
On October 28, GeLonghui announced that the self-developed PD-L1 antibody Zejemei (Suglesi monoclonal antibody injection) of Cornerstone Pharmaceuticals-B (02616.HK) has published the results of the population pharmacokinetics (PopPK) study in the well-known journal "British Journal of Clinical Pharmacology". Dr. Yang Jianxin, CEO, Chief R&D Officer, and Executive Director of Cornerstone Pharmaceuticals, said: "The PopPK study not only reveals the pharmacokinetic characteristics of Suglesi monoclonal antibody in different patient populations through modeling but also provides a standard for Suglesi monoclonal antibody."
Cornerstone Pharma-B [02616] is now trading at 2.06 Hong Kong dollars, with a rise of 10.75%.
As of 14:24, cornerstone pharmaceuticals - B [02616] reported a price of 2.06 Hong Kong dollars, up 0.2 Hong Kong dollars or 10.75% from the closing price of 1.86 Hong Kong dollars yesterday, with a turnover of 8.3702 million Hong Kong dollars. The highest price of the day was 2.06 Hong Kong dollars, and the lowest price was 1.87 Hong Kong dollars. Based on the closing price of yesterday, the 10-day average price is 1.74 Hong Kong dollars, and the 50-day average price is 1.56 Hong Kong dollars. The current pe is -5.80 times, and the 14-day relative strength index is 54.48.
CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%
No Data
No Data
